相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials
R. Bradley et al.
LANCET ONCOLOGY (2022)
Clinical characteristics and survival outcome of patients with estrogen receptor low positive breast cancer
Chuanxu Luo et al.
BREAST (2022)
De-escalation of five-year adjuvant endocrine therapy in patients with estrogen receptor-low positive (immunohistochemistry staining 1%-10%) breast cancer: Propensity-matched analysis from a prospectively maintained cohort
Yu-Wen Cai et al.
CANCER (2022)
Characterization of estrogen receptor-low-positive breast cancer
Fei Fei et al.
BREAST CANCER RESEARCH AND TREATMENT (2021)
Estrogen receptor-low breast cancer: Biology chaos and treatment paradox
Ke-Da Yu et al.
CANCER COMMUNICATIONS (2021)
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with early breast cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS
Y. H. Park et al.
ANNALS OF ONCOLOGY (2020)
Aromatase inhibitors: Role in postmenopausal breast cancer
Rajeev Kharb et al.
ARCHIV DER PHARMAZIE (2020)
The significance of highlighting the oestrogen receptor low category in breast cancer
Ivan K. Poon et al.
BRITISH JOURNAL OF CANCER (2020)
Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05)
Erik J. Blok et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05)
Erik J. Blok et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Borderline ER-Positive Primary Breast Cancer Gains No Significant Survival Benefit From Endocrine Therapy: A Systematic Review and Meta-Analysis
Tong Chen et al.
CLINICAL BREAST CANCER (2018)
First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab, in Human Epidermal Growth Factor Receptor 2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase II Trial
Mothaffar Rimawi et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial
Vivianne C. G. Tjan-Heijnen et al.
LANCET ONCOLOGY (2017)
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
G. Curigliano et al.
ANNALS OF ONCOLOGY (2017)
Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years
P. E. Goss et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update
Harold J. Burstein et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Effect of ASCO/CAP Guidelines for Determining ER Status on Molecular Subtype
Brenda Deyarmin et al.
ANNALS OF SURGICAL ONCOLOGY (2013)
Treatment of Estrogen Receptor-Positive Breast Cancer
F. Lumachi et al.
CURRENT MEDICINAL CHEMISTRY (2013)
Aromatase, aromatase inhibitors, and breast cancer
Saranya Chumsri et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2011)
Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up
Meredith M. Regan et al.
LANCET ONCOLOGY (2011)
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
M. Elizabeth H. Hammond et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Aromatase expression and outcomes in the P024 neoadjuvant endocrine therapy trial
Matthew J. Ellis et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer:: Predictive value of centrally reviewed expression of estrogen and progesterone receptors -: International Breast Cancer Study Group
Giuseppe Viale et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Aromatase inhibitors: past, present and future in breast cancer therapy
Udayan Dutta et al.
MEDICAL ONCOLOGY (2008)
Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy
XJ Cui et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: An hypothesis-generating study
M Dowsett et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Estrogen receptor-positive, progesterone receptor-negative breast cancer: Association with growth factor receptor expression and tamoxifen resistance
G Arpino et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: The Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial
IE Smith et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies
C Barba et al.
LANCET (2004)
Anastrozole demonstrates clinical and biological effectiveness in oestrogen receptor-positive breast cancers, irrespective of the erbB2 status
JM Dixon et al.
EUROPEAN JOURNAL OF CANCER (2004)
Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer:: Evidence from a phase III randomized trial
MJ Ellis et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
分享论文
